: Early Neonatal Oral Vaccine Strategy to Prevent Hyperbilirubinemia-Induced Hepatic Stellate Cell Activation and Liver Fibrosis: A Hypothesis

Title Neonatal Liver Fibrosis: Role of Hyperbilirubinemia, Hepatic Stellate Cells, T Cells, and Proposal for Early Oral Vaccine Intervention Authors F. N. Saleh Ebrahimi (primary author) Abstract Neonatal hyperbilirubinemia resulting from increased hemolysis of short-lived red blood cells and limited bile secretion can lead to premature activation of hepatic stellate cells (HSCs). This early activation promotes extracellular matrix (ECM) accumulation and collagen production, potentially predisposing neonates to liver fibrosis in later life. The immature neonatal T cell response further modulates HSC activity. Based on these mechanisms, we propose a conceptual oral vaccine intervention to modulate liver immune responses, aiming to prevent premature HSC activation, reduce ECM deposition, and decrease the risk of neonatal jaundice–associated fibrosis. This manuscript integrates current literature, experimental observations, and theoretical modeling. Portions of the text were assisted by AI tools, with all scientific interpretations verified by the author. Keywords Neonatal hyperbilirubinemia, hepatic stellate cells, liver fibrosis, T cells, oral vaccine, AI-assisted manuscript Main Text (Include the full integrated article with all sections: Neonatal liver physiology and bile production Pathway from RBC hemolysis to ROS and HSC activation T cell role in neonatal liver immune regulation Proposed oral vaccine intervention Figure/Schematic: RBC → Bilirubin → ROS → HSC → ECM → T Cells → Fibrosis → Oral Vaccine) Figures / Supplementary Schematic diagram in English (and optionally in Persian) Table summarizing physiological parameters, mechanisms, and outcomes References 1. UpToDate: Neonatal unconjugated hyperbilirubinemia 2. MSD Manual: Neonatal Hyperbilirubinemia 3. Crispe IN. Hepatic T cells and liver immune regulation. Nat Rev Immunol. 2003;3:53–64 4. Heymann F, et al. Immune-mediated mechanisms in liver fibrosis. J Hepatol. 2015;63:982–993 5. Koyama Y, Brenner DA. Immune cells and hepatic stellate cell activation. Semin Liver Dis. 2017;37:91–104 6. Takebe T, et al. Liver organogenesis and HSC activation. Nat Med. 2020;26:XXXXX 7. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 2008;88:125–172 Notes AI-assisted writing was used for structuring, formatting, and editing the manuscript. All scientific conclusions and interpretations were independently verified by the author. Schematic Description of Neonatal Liver Fibrosis Pathway and Oral Vaccine Intervention 1. Neonatal RBC Hemolysis: Short-lived red blood cells (7–10 days) undergo hemolysis, releasing unconjugated bilirubin and free iron. 2. Bilirubin Accumulation and Limited Conjugation: Immature hepatic UGT1A1 enzyme and limited bile secretion → unconjugated bilirubin accumulates in the bloodstream (hyperbilirubinemia). 3. Oxidative Stress (ROS Generation): Free bilirubin and iron increase reactive oxygen species (ROS), inducing oxidative stress on hepatocytes and surrounding microenvironment. 4. Premature Activation of Hepatic Stellate Cells (HSCs): Oxidative stress and inflammatory signals activate HSCs before full maturation. HSCs produce extracellular matrix (ECM) proteins, including collagen type I and III. 5. Liver Immune Response – T Cells: CD4+ and CD8+ T cells interact with activated HSCs via cytokines (TNF-α, IL-6). In neonates, T cell responses are immature, which may favor HSC activation and ECM deposition. 6. Long-Term Outcome – Fibrosis: Repeated or prolonged HSC activation → persistent ECM accumulation → chronic or irreversible liver fibrosis in childhood or later life. 7. Oral Vaccine Intervention (Proposed): Early oral vaccination could modulate regulatory liver immune responses. Controlled immune stimulation may prevent premature HSC activation, reduce ECM deposition, and lower the risk of neonatal jaundice–associated fibrosis. Legend/Flow: RBC Hemolysis → Unconjugated Bilirubin ↑ + Free Iron ↑ → ROS ↑ → HSC Activation → ECM/Collagen ↑ → T cell interaction → Fibrosis → Oral Vaccine (Intervention)